- Home
- DNMX vs STTK Comparison
DNMX vs STTK Comparison
Compare DNMX & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DNMX | STTK |
|---|---|---|
| Founded | 2025 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.6M | 275.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | DNMX | STTK |
|---|---|---|
| Price | $9.90 | $5.96 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.60 |
| AVG Volume (30 Days) | 74.7K | ★ 713.2K |
| Earning Date | 01-01-0001 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.87 | $0.69 |
| 52 Week High | $9.99 | $6.81 |
Technical Indicators
Market Signals| Indicator | DNMX | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 50.28 | 61.13 |
| Support Level | $9.90 | $5.75 |
| Resistance Level | $9.99 | N/A |
| Average True Range (ATR) | 0.01 | 0.37 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 66.67 | 32.41 |
Price Performance
Historical ComparisonAbout DNMX Dynamix Corporation III Class A Ordinary Shares
Dynamix Corp III is a blank check company.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.